Published: 23 March 2020
Archived: 21 August 2024

Medicines

COVID-19: Important message for Medsafe customers

In response to the Government's recommendations on COVID-19 Medsafe staff are working from home.

Contacting Medsafe:

Use email .

We are working to ensure there is minimal lapse in our service levels. However, we are unable to answer all phone calls so please contact us through the appropriate inbox listed on the Contact Us tab.

Changes to Business Processes

Submitting applications electronically

We have a new electronic system for submitting medicine applications (CMNs and NMAs). We appreciate your patience if you experience any issues while this new system is rolled out. Information on the new system can be found here.

From today please send CMN request for information responses through the electronic file transfer (EFT) or by email to medsafeapplications@health.govt.nz . Please do not send them to both.

If your medicine application has been sent by hardcopy and you have not heard from Medsafe please resubmit in electronically through the EFT

S29 returns

We will now only accept section 29 returns by email. Please send the returns to recalls@health.govt.nz. Add the text “section 29 return to the email subject line.

GMP

Please use our gmp@health.govt.nz email address for all communications and to submit applications for licences to manufacture and pack medicines, and for GMP certificates. We are, moving to desk-top audits and / or deferring audits as necessary. We will be in touch in relation to any audits that are due during this time. Please ensure that any licence application is sent to us promptly as processing time will increase.

Pharmacy Quality Audits

Medsafe has decided to temporarily suspend site audits carried out under the Pharmacy Quality Audit Programme Framework to help pharmacies maintain their work flow.

The decision will be reviewed on 1 July 2020 and the sector will be informed when auditing under the framework begins again.

Medsafe will continue to respond to public safety risks on a case by case basis, including the licensing of new premises.

Please contact Medicines Control directly ( medicinescontrol@health.govt.nz ) should you have any queries.

We are actively reviewing our day-to-day operations and will publish any updates on this website.